Pfizer's Lorbrena Shows 81% Reduction in Lung Cancer Progression, 60% Survival Rate Over Five Years

May 31, 2024, 05:00 PM

Pfizer's cancer drug Lorbrena has shown significant promise in treating ALK-positive advanced lung cancer. In a five-year study presented at the ASCO 2024 conference, Lorbrena reduced disease progression by 81% compared to Xalkori, another drug by Pfizer. The study revealed that 60% of patients treated with Lorbrena survived for five years without cancer progression, a substantial improvement over the 8% survival rate for those treated with Xalkori. The hazard ratio (HR) was 0.19, highlighting the drug's effectiveness. Lorbrena's efficacy is attributed to its ability to penetrate the brain better than Xalkori, which is crucial for patients with metastatic non-small cell lung cancer that often spreads to the brain. This drug offers new hope for patients with this rare and advanced form of lung cancer.